Last update 20 Mar 2025

Lutetium (177Lu) edotreotide

Overview

Basic Info

Drug Type
Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals
Synonyms
177Lu-edotreotide, 177Lu-edotreotide PRRT, Lu-edotreotide
+ [9]
Target
Action
antagonists
Mechanism
SSTR antagonists(Somatostatin receptor antagonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (European Union), Fast Track (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC65H89N14O18S2.Lu
InChIKeyXOPYQJXRGHFPOH-NZMVMCJSSA-K
CAS Registry321835-55-6
Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
Switzerland
02 Feb 2017
Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
Netherlands
02 Feb 2017
Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
Czechia
02 Feb 2017
Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
Australia
02 Feb 2017
Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
Italy
02 Feb 2017
Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
United States
02 Feb 2017
Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
Poland
02 Feb 2017
Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
United Kingdom
02 Feb 2017
Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
Germany
02 Feb 2017
Gastro-Enteropancreatic Neuroendocrine TumorPhase 3
France
02 Feb 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
309
(zjljpbeosf) = tmcnyqqglf yhgeixruez (rsyyqlwbqx )
Met
Positive
28 Jan 2025
(zjljpbeosf) = arhblsymqp yhgeixruez (rsyyqlwbqx )
Met
Phase 2
21
(zqfapbpixr) = gihhuironz netrdjdkkd (rapvwctqvu, 16.0 - NR)
Positive
22 Oct 2023
(panNET)
(zqfapbpixr) = lrzjnqkvsn netrdjdkkd (rapvwctqvu, 14.0 - NR)
Not Applicable
-
(GEP-NET patients)
(xxdfwozokm) = qblwkyybbx ulzihakhwr (uwmmpxujrm )
-
08 Aug 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free